Yahoo Finance Cronos Group First Quarter 2024 Earnings: Beats Expectations
Cronos Group (TSE:CRON) First Quarter 2024 Results
Key Financial Results
Revenue: US$25.3m (up 26% from 1Q 2023).
Net loss: US$2.24m (loss narrowed by 88% from 1Q 2023).
US$0.01 loss per share (improved from US$0.05 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Cronos Group Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 7.0%. Earnings per share (EPS) also surpassed analyst estimates by 1.9%.
Looking ahead, revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in Canada.
Performance of the Canadian Pharmaceuticals industry.
The company's shares are up 4.4% from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on Cronos Group's balance sheet.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
